Oncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.com

by · The Cerbat Gem

Research analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Oncternal Therapeutics in a report on Friday, May 31st.

Check Out Our Latest Stock Analysis on ONCT

Oncternal Therapeutics Price Performance

Shares of ONCT opened at $7.60 on Friday. Oncternal Therapeutics has a one year low of $5.57 and a one year high of $13.14. The company has a market cap of $22.50 million, a P/E ratio of -0.62 and a beta of 1.38. The firm has a 50 day simple moving average of $8.54 and a two-hundred day simple moving average of $8.82.

Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($2.83) EPS for the quarter, beating the consensus estimate of ($2.88) by $0.05. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.18 million. During the same period in the previous year, the business earned ($4.00) earnings per share. On average, analysts expect that Oncternal Therapeutics will post -11.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oncternal Therapeutics news, Director Robert James Wills acquired 3,086 shares of Oncternal Therapeutics stock in a transaction that occurred on Monday, April 8th. The stock was acquired at an average cost of $8.96 per share, for a total transaction of $27,650.56. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at $89,600. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC acquired a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned 0.94% of Oncternal Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

(Get Free Report)

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.

Recommended Stories